Calculus bovis sativus is named as a drug or biological intervention in 5 clinical trials in our China trial register, 3 of which are recruiting. Lead sponsors include Tongji Hospital (4) and Huazhong University of Science and Technology (1). Registered phase: Not applicable. Conditions studied include Encephalitis; Encephalitis, Viral; Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody.
| NCT ID | Study | Phase | Status |
|---|---|---|---|
| NCT06474507 | Efficacy and Safety of Calculus Bovis Sativus (CBS) for Ischemic Cerebral Vascular Disease (CBSinICVD) (ClinicalTrials.gov ↗) Ischemic Cerebrovascular Disease, Acute Ischemic Stroke, Cerebral Small Vessel Diseases |
Not applicable | Recruiting |
| NCT06474520 | Efficacy and Safety of Calculus Bovis Sativus (CBS) for Idiopathic Inflammatory Demyelinating Disease (CBSinIIDD) (ClinicalTrials.gov ↗) Idiopathic Inflammatory Demyelinating Disease, Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder |
Not applicable | Recruiting |
| NCT06584045 | Efficacy and Safety of Calculus Bovis Sativus (CBS) for Adult Encephalitis (CBSinEncephalitis) (ClinicalTrials.gov ↗) Encephalitis, Encephalitis, Viral, Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody |
Not applicable | Recruiting |
| NCT07080632 | Efficacy and Safety of Calculus Bovis Sativus (CBS) for Intracerebral Hemorrhage(CBSinICH) (ClinicalTrials.gov ↗) Intracerebral Hemorrhage, Brain Hemorrhage |
Not applicable | Not yet open |
| NCT07085962 | Efficacy and Safety of Calculus Bovis Sativus in Adults With MAFLD (ClinicalTrials.gov ↗) Metabolic Dysfunction-associated Fatty Liver Disease |
Not applicable | Not yet open |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Encephalitis | 1 |
| Encephalitis, Viral | 1 |
| Autoimmune Encephalitis Caused by N-Methyl D-Aspartate Receptor Antibody | 1 |
| Autoimmune Encephalitis | 1 |
| Intracerebral Hemorrhage | 1 |
| Brain Hemorrhage | 1 |
| Ischemic Cerebrovascular Disease | 1 |
| Acute Ischemic Stroke | 1 |
| Cerebral Small Vessel Diseases | 1 |
| Metabolic Dysfunction-associated Fatty Liver Disease | 1 |
| Idiopathic Inflammatory Demyelinating Disease | 1 |
| Multiple Sclerosis | 1 |
| Neuromyelitis Optica Spectrum Disorder | 1 |
| Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease | 1 |
| Lead sponsor | Trials |
|---|---|
| Tongji Hospital | 4 |
| Huazhong University of Science and Technology | 1 |
| Register | Calculus bovis sativus trials |
|---|---|
| Clinical trials in China | 5 |
A trial with sites in more than one country appears in each of those registers.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Calculus bovis sativus works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Calculus bovis sativus (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 24 Sep 2026.